Literature DB >> 25643638

Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.

Mi Na Kim1, Seung Up Kim1,2, Beom Kyung Kim1,2, Jun Yong Park1,2, Do Young Kim1,2, Sang Hoon Ahn1,2,3, Ki Jun Song4, Young Nyun Park5, Kwang-Hyub Han1,2,3.   

Abstract

UNLABELLED: Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high-risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical evidence of cirrhosis. A total of 2,876 CHB patients without clinical cirrhosis who received TE examinations between April 2006 and December 2012 were enrolled in this prospective study. SCC was defined as a nonclinical cirrhosis, but with a liver stiffness (LS) value ≥13 kilopascals (kPa). Mean age of the study population was 46.1 years, and male gender was predominant (n = 1,775; 61.7%). Mean LS value was 7.9 kPa, and SCC was identified in 285 (9.9%) patients. During the median follow-up period of 48.9 months (range, 6.6-96.2), HCC developed in 16 patients (13.3 per 1,000 person-years) in the SCC group and 36 (3.4 per 1,000 person-years) in the non-SCC group. Cumulative incidence rate of HCC in the SCC group was significantly higher than that in the non-SCC group (P < 0.001, log-rank test). On multivariate analysis, SCC was independently associated with a risk of developing HCC, regardless of antiviral therapy (without antiviral therapy: hazard ratio [HR]: 4.680; 95% confidence interval [CI]: 1.187-18.441; P = 0.027; with antiviral therapy: HR, 3.344; 95% CI: 1.526-7.328; P = 0.003).
CONCLUSION: TE can identify CHB patients with SCC who are at increased risk of developing HCC, even when cirrhosis is not clinically apparent.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25643638     DOI: 10.1002/hep.27735

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis.

Authors:  Amine Benmassaoud; Roy Nitulescu; Thomas Pembroke; Alex S Halme; Peter Ghali; Marc Deschenes; Philip Wong; Marina B Klein; Giada Sebastiani
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

Review 2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

3.  Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.

Authors:  Young Eun Chon; Jun Yong Park; Sung-Min Myoung; Kyu Sik Jung; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

4.  Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.

Authors:  Mi Young Jeon; Hye Won Lee; Seung Up Kim; Ja Yoon Heo; Sojung Han; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2017-02-21       Impact factor: 6.047

5.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

6.  Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.

Authors:  Jia-Li Wang; Xin-Fang Du; Shao-Long Chen; Yi-Qi Yu; Jing Wang; Xi-Qi Hu; Ling-Yun Shao; Jia-Zhen Chen; Xin-Hua Weng; Wen-Hong Zhang
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 7.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

8.  Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease.

Authors:  Dong Ho Lee; Jeong Min Lee; Won Chang; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-02-27       Impact factor: 5.315

Review 9.  The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

Authors:  Silvia Affo; Le-Xing Yu; Robert F Schwabe
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

10.  Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma.

Authors:  Tianying Zheng; Hanyu Jiang; Yi Wei; Zixing Huang; Jie Chen; Ting Duan; Bin Song
Journal:  Chin J Cancer Res       Date:  2018-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.